Trial Search Results

Sirolimus as Primary Therapy for the Treatment of Chronic Graft Versus Host Disease

Evaluate the clinical activity of sirolimus in combination with cyclosporine and corticosteroids as first line therapy for the treatment of chronic Graft Versus Host Disease.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Stanford Investigator(s):

Intervention(s):

  • Procedure: high dose chemotherapy and autologous hematopoietic cell transplant

Phase:

Phase 2

Eligibility


Inclusion Criteria:- active chronic GvHD

   - ANC > 1000/mm^3

   - therapeutic cyclosporine

Exclusion Criteria:- uncontrolled systemic infection

- elevated serum creatinine

Ages Eligible for Study

18 Years - 70 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
BMT Referrals
6507230822
Not Recruiting